Clinical trials of atrasentan in hormone-refractory prostate cancer.
Lee
David
D
D000077868:Atrasentan; D018450:Disease Progression; D004311:Double-Blind Method; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010146:Pain / Q000517:prevention & control; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011759:Pyrrolidines / Q000627:therapeutic use*; D011788:Quality of Life; D016019:Survival Analysis; D016896:Treatment Outcome
D019332:Endothelin-1; D011759:Pyrrolidines; D017430:Prostate-Specific Antigen; D000077868:Atrasentan